- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03002766
Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast (DCIS)
21 december 2016 uppdaterad av: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.
By this non-randomized prospective study, it's evaluated the outcome of patients underwent BCS for DCIS at whom an established score system to address adjuvant therapies have been prospectively applied, according to the wideness of free margins.
Between March 2000 and April 2006, 224 patients were enrolled and followed within the study.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
224
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
MI
-
Milano, MI, Italien, 20133
- Massimiliano Gennaro
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Kvinna
Beskrivning
Inclusion Criteria:
- age >18 years;
- female candidate to breast conservative surgery
Exclusion Criteria:
- female with previous omolateral or controlateral breast cancer;
- female with previous radiotherapy (RT).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Ipsilateral Breast Tumor Recurrence (IBTR)
Tidsram: six years
|
six years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Contralateral breast cancer (CBC)
Tidsram: six years
|
the side effects of radiotherapy may outweigh the reduction in the risk of IBTR
|
six years
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Massimiliano Gennaro, MD, Fondazione IRCCS Istituto Nazionale Tumori
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J AM Stat Assoc 53:457-481, 1958.
- Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998 Feb;16(2):441-52. doi: 10.1200/JCO.1998.16.2.441.
- Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4054-9. doi: 10.1200/JCO.2013.49.5077. Epub 2013 Sep 16.
- Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008 Mar 10;26(8):1247-52. doi: 10.1200/JCO.2007.12.7969. Epub 2008 Feb 4.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039.
- Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011 Jan;12(1):21-9. doi: 10.1016/S1470-2045(10)70266-7. Epub 2010 Dec 7.
- Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12;353(9169):1993-2000. doi: 10.1016/S0140-6736(99)05036-9.
- Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.
- Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.
- Povoski SP, Jimenez RE, Wang WP, Xu RX. Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer. BMC Cancer. 2009 Jul 27;9:254. doi: 10.1186/1471-2407-9-254.
- Rizzo M, Iyengar R, Gabram SG, Park J, Birdsong G, Chandler KL, Mosunjac MB. The effects of additional tumor cavity sampling at the time of breast-conserving surgery on final margin status, volume of resection, and pathologist workload. Ann Surg Oncol. 2010 Jan;17(1):228-34. doi: 10.1245/s10434-009-0643-x. Epub 2009 Jul 28.
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163-70. No abstract available.
- EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006 Jul 20;24(21):3381-7. doi: 10.1200/JCO.2006.06.1366. Epub 2006 Jun 26.
- Rutgers EJ; EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer. 2001 Mar;37(4):447-53. doi: 10.1016/s0959-8049(00)00386-5. No abstract available.
- Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner SH, Holland R, Hughes KS, Mansel RE, Margolese R, Mendelson EB, Olivotto IA, Palazzo JP, Solin LJ; Consensus Conference Committee. Consensus conference on breast conservation. J Am Coll Surg. 2006 Aug;203(2):198-207. doi: 10.1016/j.jamcollsurg.2006.04.009. No abstract available.
- Rutqvist LE, Rose C, Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol. 2003;42(5-6):532-45. doi: 10.1080/02841860310014444.
- Healy C, Allen RJ Sr. The evolution of perforator flap breast reconstruction: twenty years after the first DIEP flap. J Reconstr Microsurg. 2014 Feb;30(2):121-5. doi: 10.1055/s-0033-1357272. Epub 2013 Oct 25.
- Kasem A, Wazir U, Headon H, Mokbel K. Breast lipofilling: a review of current practice. Arch Plast Surg. 2015 Mar;42(2):126-30. doi: 10.5999/aps.2015.42.2.126. Epub 2015 Mar 16.
- Gennaro M, Ferraris C, Guida V, Tomasic G, Carcangiu ML, Greco M. Conservative surgery in breast cancer. Significance of resection margins. Breast. 2001 Oct;10(5):432-7. doi: 10.1054/brst.2001.0297.
- Macdonald HR, Silverstein MJ, Lee LA, Ye W, Sanghavi P, Holmes DR, Silberman H, Lagios M. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006 Oct;192(4):420-2. doi: 10.1016/j.amjsurg.2006.06.031.
- Van Zee KJ, Liberman L, Samli B, Tran KN, McCormick B, Petrek JA, Rosen PP, Borgen PI. Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999 Nov 1;86(9):1757-67. doi: 10.1002/(sici)1097-0142(19991101)86:93.0.co;2-v.
- Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999 Aug 1;86(3):429-38. doi: 10.1002/(sici)1097-0142(19990801)86:33.0.co;2-y.
- Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Dexter T, Jones A, Reid L, Da Silva L, Shin SJ, Hardisson D, Ashworth A, Schmitt FC, Palacios J, Lakhani SR. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008 Jul;215(3):231-44. doi: 10.1002/path.2358.
- Lesurf R, Aure MR, Mork HH, Vitelli V; Oslo Breast Cancer Research Consortium (OSBREAC); Lundgren S, Borresen-Dale AL, Kristensen V, Warnberg F, Hallett M, Sorlie T. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. Cell Rep. 2016 Jul 26;16(4):1166-1179. doi: 10.1016/j.celrep.2016.06.051. Epub 2016 Jul 7.
- Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996 Jun 1;77(11):2267-74. doi: 10.1002/(SICI)1097-0142(19960601)77:113.0.CO;2-V.
- Silverstein MJ, Lagios MD. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J. 2015 Mar-Apr;21(2):127-32. doi: 10.1111/tbj.12368. Epub 2015 Jan 20.
- Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, DeSantis S, Barry WT, Golshan M. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. J Clin Oncol. 2016 Apr 10;34(11):1190-6. doi: 10.1200/JCO.2015.65.1869. Epub 2016 Feb 1.
- Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol. 2016 Oct;17(10):e442-e451. doi: 10.1016/S1470-2045(16)30367-9.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 mars 2000
Primärt slutförande (Faktisk)
1 april 2006
Avslutad studie (Faktisk)
1 april 2006
Studieregistreringsdatum
Först inskickad
2 december 2016
Först inskickad som uppfyllde QC-kriterierna
21 december 2016
Första postat (Uppskatta)
26 december 2016
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
26 december 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
21 december 2016
Senast verifierad
1 december 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hudsjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Adenocarcinom
- Neoplasmer, körtel och epitel
- Bröstsjukdomar
- Neoplasmer, duktal, lobulär och medullär
- Carcinom in situ
- Bröstneoplasmer
- Carcinom
- Bröstkarcinom på plats
- Karcinom, Ductal
- Karcinom, intraduktalt, icke-infiltrerande
Andra studie-ID-nummer
- 67/13
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Carcinom Bröst
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeOral Cavity Carcinom | Oral intraepitelial neoplasiFörenta staterna
-
Endo PharmaceuticalsAvslutad
-
Indira Gandhi Medical College, ShimlaOkänd
Kliniska prövningar på Breast conservative surgery
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Sunnybrook Health Sciences CentreOkänd
-
The Leeds Teaching Hospitals NHS TrustUniversity of Leeds; 4DPathHar inte rekryterat ännuBröstcancerStorbritannien
-
Medical University of GrazAvslutadLivskvalité | Tillfredsställelse, patient | Komplikationer, Postoperativ/PerioperativÖsterrike
-
Diakonessenhuis, UtrechtRekryteringLivskvalité | Sömnapné, obstruktivNederländerna
-
Royal Surrey County Hospital NHS Foundation TrustOkändÄggstockscancer | Äggledarcancer | Peritoneal cancer | Ovarial neoplasm | Ovarian Neoplasm EpitelialStorbritannien
-
AirXpanders, Inc.AvslutadBröstcancer | BröstrekonstruktionAustralien
-
Thurgau Breast CenterRekrytering
-
Institut du Cancer de Montpellier - Val d'AurelleRekryteringBröstcancer | Kapselkontraktur associerad med bröstimplantatFrankrike
-
SenoRx, Inc.C. R. BardAvslutad
-
Mayo ClinicSusan G. Komen Breast Cancer FoundationAvslutad